Spots Global Cancer Trial Database for Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema

Official Title: Contribution of an Endermologie LPG Cellu M6 Treatment in the Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema, During an Intensive Decongestive Treatment.

Study ID: NCT02506530

Conditions

Lymphedema

Interventions

intensive decongestive treatment

Cellu M6

Study Description

Brief Summary: This study will assess the benefit of LPG Cellu M6 in addition of intensive decongestive treatment in reducing secondary lymphoedema in breast cancer.

Detailed Description: The main objective of the study is to assess the proportion of successfully treated patients (success rate). That is to say patients having a reduction of excess arm volume ≥ 30% after 5 days of three types of treatment for secondary lymphoedema : Group 1: standard intensive decongestive therapy for 5 days (bandages + manual lymphatic drainage). Group 2: standard intensive decongestive therapy (bandages + manual lymphatic drainage) + Cellu M6 for 5 days Group 3: Bandages + Cellu M6 for 5 days Symptomatic treatment of lymphoedema reference is intensive decongestive therapy including manual lymphatic drainage, compression of multicomponent bandaging, therapeutic exercise and skin care (HAS 2012 ISL International Society of Lymphology, 2013).